| Title |
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
|
|---|---|
| Published in |
JAMA: Journal of the American Medical Association, July 2018
|
| DOI | 10.1001/jama.2018.8431 |
| Pubmed ID | |
| Authors |
Michael S. Saag, Constance A. Benson, Rajesh T. Gandhi, Jennifer F. Hoy, Raphael J. Landovitz, Michael J. Mugavero, Paul E. Sax, Davey M. Smith, Melanie A. Thompson, Susan P. Buchbinder, Carlos del Rio, Joseph J. Eron, Gerd Fätkenheuer, Huldrych F. Günthard, Jean-Michel Molina, Donna M. Jacobsen, Paul A. Volberding |
| Abstract |
Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. To evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for individuals at risk. New evidence collected since the International Antiviral Society-USA 2016 recommendations via monthly PubMed and EMBASE literature searches up to April 2018; data presented at peer-reviewed scientific conferences. A volunteer panel of experts in HIV research and patient care considered these data and updated previous recommendations. ART is recommended for virtually all HIV-infected individuals, as soon as possible after HIV diagnosis. Immediate initiation (eg, rapid start), if clinically appropriate, requires adequate staffing, specialized services, and careful selection of medical therapy. An integrase strand transfer inhibitor (InSTI) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is generally recommended for initial therapy, with unique patient circumstances (eg, concomitant diseases and conditions, potential for pregnancy, cost) guiding the treatment choice. CD4 cell count, HIV RNA level, genotype, and other laboratory tests for general health and co-infections are recommended at specified points before and during ART. If a regimen switch is indicated, treatment history, tolerability, adherence, and drug resistance history should first be assessed; 2 or 3 active drugs are recommended for a new regimen. HIV testing is recommended at least once for anyone who has ever been sexually active and more often for individuals at ongoing risk for infection. Preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and appropriate monitoring is recommended for individuals at risk for HIV. Advances in HIV prevention and treatment with antiretroviral drugs continue to improve clinical management and outcomes for individuals at risk for and living with HIV. |
X Demographics
The data shown below were collected from the profiles of 199 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 58 | 29% |
| Spain | 23 | 12% |
| Mexico | 9 | 5% |
| Colombia | 7 | 4% |
| Venezuela, Bolivarian Republic of | 5 | 3% |
| Philippines | 3 | 2% |
| Peru | 3 | 2% |
| Chile | 3 | 2% |
| India | 2 | 1% |
| Other | 23 | 12% |
| Unknown | 63 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 143 | 72% |
| Practitioners (doctors, other healthcare professionals) | 32 | 16% |
| Scientists | 19 | 10% |
| Science communicators (journalists, bloggers, editors) | 5 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 526 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 526 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 67 | 13% |
| Researcher | 54 | 10% |
| Student > Bachelor | 54 | 10% |
| Other | 37 | 7% |
| Student > Ph. D. Student | 35 | 7% |
| Other | 106 | 20% |
| Unknown | 173 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 135 | 26% |
| Nursing and Health Professions | 38 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 36 | 7% |
| Biochemistry, Genetics and Molecular Biology | 29 | 6% |
| Immunology and Microbiology | 18 | 3% |
| Other | 84 | 16% |
| Unknown | 186 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 253. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2021.
All research outputs
#148,387
of 25,880,422 outputs
Outputs from JAMA: Journal of the American Medical Association
#2,238
of 36,780 outputs
Outputs of similar age
#2,990
of 343,578 outputs
Outputs of similar age from JAMA: Journal of the American Medical Association
#41
of 396 outputs
Altmetric has tracked 25,880,422 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 36,780 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 72.7. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,578 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 396 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.